MX2020007985A - Inhibicion del canal ionico receptor de potencial transitorio a1. - Google Patents

Inhibicion del canal ionico receptor de potencial transitorio a1.

Info

Publication number
MX2020007985A
MX2020007985A MX2020007985A MX2020007985A MX2020007985A MX 2020007985 A MX2020007985 A MX 2020007985A MX 2020007985 A MX2020007985 A MX 2020007985A MX 2020007985 A MX2020007985 A MX 2020007985A MX 2020007985 A MX2020007985 A MX 2020007985A
Authority
MX
Mexico
Prior art keywords
inhibiting
ion channel
transient receptor
receptor potential
trpa1
Prior art date
Application number
MX2020007985A
Other languages
English (en)
Inventor
Xinyuan Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2020007985A publication Critical patent/MX2020007985A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención se refiere a compuestos farmacéuticos de la Fórmula (1), o una composición o sal aceptable desde el punto de vista farmacéutico de estos, y a métodos de su uso para el tratamiento del dolor, afecciones respiratorias, así como para inhibir el canal iónico receptor de potencial transitorio Al (TRPA1).
MX2020007985A 2018-01-31 2019-01-30 Inhibicion del canal ionico receptor de potencial transitorio a1. MX2020007985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624276P 2018-01-31 2018-01-31
PCT/US2019/015769 WO2019152465A1 (en) 2018-01-31 2019-01-30 Inhibiting the transient receptor potential a1 ion channel

Publications (1)

Publication Number Publication Date
MX2020007985A true MX2020007985A (es) 2020-09-09

Family

ID=65409625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007985A MX2020007985A (es) 2018-01-31 2019-01-30 Inhibicion del canal ionico receptor de potencial transitorio a1.

Country Status (14)

Country Link
US (1) US11161849B2 (es)
EP (2) EP4233871A3 (es)
JP (1) JP7025555B2 (es)
KR (1) KR102418211B1 (es)
CN (1) CN111655693B (es)
AU (1) AU2019216247B2 (es)
BR (1) BR112020014584A2 (es)
CA (1) CA3088551C (es)
EA (1) EA202091604A1 (es)
IL (1) IL276194B2 (es)
MX (1) MX2020007985A (es)
SA (1) SA520412533B1 (es)
TW (1) TW201940486A (es)
WO (1) WO2019152465A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233752A1 (en) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Trpa1 antagonists for the treatment of diseases associated with pain and inflammation
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
CN115475171A (zh) * 2021-06-16 2022-12-16 中国医学科学院医药生物技术研究所 一种具有抗冠状病毒活性的化合物及其应用
CN114671876B (zh) * 2022-04-27 2023-10-03 成都施贝康生物医药科技有限公司 新型茶碱类化合物、异构体或盐及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423819B (zh) 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
EP3184527B1 (en) 2007-06-22 2020-01-29 Eli Lilly and Company 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010036821A1 (en) 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
TW201311690A (zh) * 2011-08-09 2013-03-16 Hydra Biosciences Inc 抑制暫態受體電位離子通道ｔｒｐａ１
US20140163048A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US20140158116A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Inhibiting trpa1 for the treatment of asthma
US9961651B2 (en) * 2012-08-17 2018-05-01 Intel Corporation Multi-channel power control
WO2014113671A1 (en) * 2013-01-18 2014-07-24 Cubist Pharmaceuticals, Inc. Inhibiting the transient receptor potential a1 ion channel
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PT3193880T (pt) * 2014-09-19 2020-06-19 Lilly Co Eli Inibição do canal iónico receptor de potencial transitório a1

Also Published As

Publication number Publication date
CN111655693A (zh) 2020-09-11
EA202091604A1 (ru) 2020-10-26
AU2019216247A1 (en) 2020-07-16
EP3746445A1 (en) 2020-12-09
AU2019216247B2 (en) 2021-08-26
IL276194A (en) 2020-09-30
SA520412533B1 (ar) 2022-12-27
KR102418211B1 (ko) 2022-07-08
WO2019152465A1 (en) 2019-08-08
US11161849B2 (en) 2021-11-02
CN111655693B (zh) 2023-03-28
US20200392136A1 (en) 2020-12-17
KR20200105496A (ko) 2020-09-07
JP2021512075A (ja) 2021-05-13
JP7025555B2 (ja) 2022-02-24
CA3088551C (en) 2023-01-24
EP4233871A3 (en) 2023-11-01
CA3088551A1 (en) 2019-08-08
BR112020014584A2 (pt) 2020-12-01
EP4233871A2 (en) 2023-08-30
IL276194B2 (en) 2023-06-01
TW201940486A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2013012588A (es) Inhibidores de cinasa.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
PH12020550594A1 (en) New alcoxyamino derivatives for treating pain and pain related conditions
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators